Liz Parrish, founder of BioViva Sciences discusses the objective improvements in her biomarkers after taking gene therapy for telomerase and follastatin.
So it turns out that today is #nationalsuperheroday so I thought I would revisit this Liz Parrish telomerase gene therapy story. She states that in September of 2015, she took gene therapy to introduce supernormal numbers of copies of telomerase and follistatin into her genome. There has been a lot of buzz around this and there are three linked stories …
Gene Therapy CEO and “patient zero” says her telomere length went from 6,710 DNA base pairs to 7,330 base pair in just six months.
We chat with BioViva CEO Liz Parrish, who has heroically injected herself with a live virus meant to transfect her with two genes- telomerase and follistatin.
Meet Liz Parris, CEO of BioViva, who last week divulged that that she herself was actually “Patient zero” or first patient was transfected. We are left to hope for the best, say thanks to Liz Parrish for taking a bold step towards her own personal immortality, and will watch and wait.